Skip to content

Jules A A C Heuberger

2 papers in the library · 17 citations · publishing 2024-2026

Papers

Sort Most recent Most cited

Sustained pharmacodynamic effects of S-ketamine on cortical excitability and resting-state brain activity: A randomized, placebo-controlled trial.

British Journal of Clinical Pharmacology June 24, 2026 Catherine M K E De Cuba, Annika A De Goede, Joost C Van Mechelen et al.

This study aimed to investigate a set of pharmacodynamic biomarkers reflecting acute, delayed and sustained central nervous system effects of S-ketamine, used as a tool compound for rapid-acting antidepressant activity, with the goal of informing biomarker strategies for delayed antidepressant effects. In this randomized, double-blind, double-dummy, placebo-controlled, 4-way crossover study in...

Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ9-Tetrahydrocannabinol Without Improving Its Analgesic Properties.

Clinical pharmacology and therapeutics November 1, 2024 Andriy A Gorbenko, Jules A A C Heuberger, Linda E. Klumpers et al. 17 citations

Cannabidiol (CBD), the main non-intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ9-tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial investigated the hypothesis that CBD counteracts the adverse effects of THC and thereby potentially improves the tolerability of cannabis as an analgesic. A...